TeneoBio - About the company
TeneoBio is an acquired company based in Menlo Park (United States), founded in 2007 by Roland Buelow. It operates as a Developer of antibodies by using a transgenic rat platform against cancer, autoimmunity, and infectious diseases. TeneoBio has raised an undisclosed amount in funding, with last known valuation of $*****. The company has 2051 active competitors, including 449 funded and 322 that have exited. Its top competitors include companies like Antheia, Synthego and Axol Bioscience.
Company Details
TeneoBio is a developer of antibodies by using a transgenic rat platform against cancer, autoimmunity, and infectious diseases. It is a biotechnology company that is developing a new class of biologics, Human Heavy Chain Antibodies as therapeutics against multiple diseases. It has several products in pre-clinical development for the treatment of multiple myeloma, prostate cancer, immune disorders, and AIDS. Its antibody discovery engine is based on UniRat, a proprietary heavy chain only, human immunoglobulin transgenic. They apply a novel sequence-based discovery approach using NGS, bioinformatics, and high-throughput recombinant protein expression.
- Website
- www.teneobio.com/
- Email ID
- *****@teneobio.com
- Registered Address
- Menlo Park, California
Key Metrics
Founded Year
2007
Location
Menlo Park, United States
Stage
Acquired
Latest Funding Round
Last Known Valuation
$***** as on Jul 28, 2021
Investors
Ranked
134th among 2051 active competitors
Employee Count
50 - 199 as on Mar 01, 2026
Exit Details
Acquired by Amgen (Jul 27, 2021)
Legal entities associated with TeneoBio
TeneoBio is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Teneobio, Inc. CIN: 270715729 , Belgium, Active | Aug 06, 2009 | - | - | - |
TeneoBio's acquisition details
Click here to take a look at TeneoBio's acquisition in detail
Sign up to download TeneoBio's company profile
TeneoBio's funding and investors
TeneoBio has raised funding over 5 rounds. Its first funding round was on Mar 01, 2018. Its latest funding round was a Grant (prize money) round on Sep 01, 2020 for $*****. 1 investor participated in its latest round. TeneoBio has 2 institutional investors.
Here is the list of recent funding rounds of TeneoBio:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 01, 2020 | 4197145 | Grant (prize money) | 8254533 | 8786440 | 6033997 | 4639054 |
Sep 19, 2019 | 2614386 | Grant (prize money) | 3304470 | 9069345 | 8395823 | |
Aug 12, 2019 | 2793836 | Grant (prize money) | 9060526 | 3929055 | 6600807 |
View details of TeneoBio's funding rounds and investors
TeneoBio's founders and board of directors
Founder? Claim ProfileThe founders of TeneoBio is Roland Buelow.
Here are the details of TeneoBio's key team members:
- Roland Buelow: Founder & CEO of TeneoBio and founder of 1 other company.
View details of TeneoBio's Founder profiles and Board Members
TeneoBio's employee count trend
TeneoBio has 50 - 199 employees as of Mar 26. Here is TeneoBio's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
TeneoBio's Competitors and alternates
Top competitors of TeneoBio include Antheia, Synthego and Axol Bioscience. Here is the list of Top 10 competitors of TeneoBio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Antheia 2013, Palo Alto (United States), Series C | Genetically engineered yeast cells to produce medicinal products | $176M | 68/100 | |
2nd | Synthego 2012, Redwood City (United States), Acquired | Manufacturer of custom CRISPR gene editors and molecular biology reagents | $460M | 67/100 | |
3rd | Axol Bioscience 2013, Cambridge (United Kingdom), Series A | Provider of human cells, reagents, and reprogramming services | $13.3M | 65/100 | |
4th | Developer of antibody drug conjugates for the treatment of broad spectrum diseases | $195M | 65/100 | ||
5th | Novogene Corporation 2011, Beijing (China), Series B | Provider of genomic services and solutions | $75M | 64/100 | |
6th | Korro Bio 2018, Cambridge (United States), Public | Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases | $4M | 64/100 | |
7th | Avalyn Pharma 2011, Seattle (United States), Public | Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis | $389M | 63/100 | |
8th | Developer of oral non-viral gene therapy platform | $54M | 63/100 | ||
9th | Watchmaker Genomics 2018, Boulder (United States), Series A | Developer of gene-editing technology | $48.3M | 63/100 | |
10th | One Biosciences 2020, Paris (France), Series A | Developer of single-cell therapeutics solutions to treat multiple health disorders | $22.4M | 63/100 | |
134th | TeneoBio 2007, Menlo Park (United States), Acquired | Developer of antibodies by using a transgenic rat platform against cancer, autoimmunity, and infectious diseases | - | 48/100 |
Looking for more details on TeneoBio's competitors? Click here to see the top ones
TeneoBio's Investments and acquisitions
TeneoBio has made no investments or acquisitions yet.
Reports related to TeneoBio
Here is the latest report on TeneoBio's sector:
News related to TeneoBio
•
Newly-Formed Ancora Biotech Will Continue Operations of Teneobio Spin-offs After Successful Acquisition of Teneobio by AmgenBusiness Wire•Oct 27, 2021•Amgen, TeneoBio
•
Amgen Successfully Completes Acquisition Of Teneobio, Inc.Investing News•Oct 19, 2021•Amgen, TeneoBio
•
Gilead-partnered Teneobio and its next-gen cancer work snapped up by Amgen for $2.5BFierce Biotech•Jul 28, 2021•Amgen, TeneoBio
•
•
AbbVie Exercises Right to Acquire TeneoOne and Lead Asset TNB-383B for the Potential Treatment of Relapsed or Refractory Multiple MyelomaInvesting News•Jun 24, 2021•AbbVie, TeneoBio, LEAD
•
•
Teneobio Announces FDA Clearance of IND for TNB-585 and Initiation of Phase I Clinical Studies for Metastatic Castrate Resistant Prostate CancerPipelinereview•Jan 26, 2021•TeneoBio
•
Teneobio Reports Initial Data from a Phase I Study of TNB-383B in Relapsed Refractory Multiple MyelomaPipelinereview•Dec 08, 2020•TeneoBio
•
Kite licences Teneobio’s multiple myeloma targeting antibodiesPharmaceutical Technology•Apr 03, 2020•Kite Pharma, TeneoBio, Gilead
•
Gilead in-licenses multiple CAR antibodies from TeneoBioSeeking Alpha•Apr 02, 2020•Gilead, TeneoBio, Kite Pharma
Are you a Founder ?
FAQs about TeneoBio
Explore our recently published companies
- On Tap Consulting - San Francisco based, 2013 founded, Unfunded company
- Jagmohan Pla-Mach - Mumbai based, 1980 founded, Unfunded company
- Narendra Polychem - Faridabad based, 2002 founded, Unfunded company
- Jai Dadi Group - Kolkata based, 1983 founded, Unfunded company
- Ronda - Lausen based, 1946 founded, Public company
- YUKE - Krefeld based, 1989 founded, Public company